Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Galectin-7 as a potential predictive marker of chemo- and/or radio-therapy resistance in oral squamous cell carcinoma.

Matsukawa S, Morita K, Negishi A, Harada H, Nakajima Y, Shimamoto H, Tomioka H, Tanaka K, Ono M, Yamada T, Omura K.

Cancer Med. 2014 Apr;3(2):349-61. doi: 10.1002/cam4.195. Epub 2014 Feb 7.

2.

Overexpression of Galectin-1 is negatively correlated with pathologic differentiation grade in oral squamous cell carcinoma.

Zhong LP, Wei KJ, Yang X, Pan HY, Ye DX, Wang LZ, Zhang ZY.

J Cancer Res Clin Oncol. 2010 Oct;136(10):1527-35. doi: 10.1007/s00432-010-0810-2. Epub 2010 Feb 16.

PMID:
20157731
3.

Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis.

Zhu X, Ding M, Yu ML, Feng MX, Tan LJ, Zhao FK.

BMC Cancer. 2010 Jun 15;10:290. doi: 10.1186/1471-2407-10-290.

4.

GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.

Yang CZ, Ma J, Zhu DW, Liu Y, Montgomery B, Wang LZ, Li J, Zhang ZY, Zhang CP, Zhong LP.

Ann Oncol. 2014 Jun;25(6):1215-22. doi: 10.1093/annonc/mdu120. Epub 2014 Mar 24.

5.

Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.

Zhu DW, Liu Y, Yang X, Yang CZ, Ma J, Yang X, Qiao JK, Wang LZ, Li J, Zhang CP, Zhang ZY, Zhong LP.

BMC Cancer. 2013 Jun 21;13:301. doi: 10.1186/1471-2407-13-301.

6.

FAP-1 and NF-κB expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis.

Nariai Y, Mishima K, Yoshimura Y, Sekine J.

Int J Oral Maxillofac Surg. 2011 Apr;40(4):419-26. doi: 10.1016/j.ijom.2010.10.020. Epub 2010 Dec 19.

PMID:
21176871
7.

Friend leukaemia insertion (Fli)-1 is a prediction marker candidate for radiotherapy resistant oral squamous cell carcinoma.

Shintani S, Hamakawa H, Nakashiro K, Shirota T, Hatori M, Tanaka M, Kuroshita Y, Kurokawa Y.

Int J Oral Maxillofac Surg. 2010 Nov;39(11):1115-9. doi: 10.1016/j.ijom.2010.02.027. Epub 2010 Aug 14.

PMID:
20709497
8.

Potential Salivary Proteomic Markers of Oral Squamous Cell Carcinoma.

Gallo C, Ciavarella D, Santarelli A, Ranieri E, Colella G, Lo Muzio L, Lo Russo L.

Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):55-61.

PMID:
26708599
9.

FLOT-2 is an independent prognostic marker in oral squamous cell carcinoma.

Wen Q, Alnemah MM, Luo J, Wang W, Chu S, Chen L, Li J, Xu L, Li M, Zhou J, Fan S.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8236-43. eCollection 2015.

10.

Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.

Chi LM, Lee CW, Chang KP, Hao SP, Lee HM, Liang Y, Hsueh C, Yu CJ, Lee IN, Chang YJ, Lee SY, Yeh YM, Chang YS, Chien KY, Yu JS.

Mol Cell Proteomics. 2009 Jul;8(7):1453-74. doi: 10.1074/mcp.M800460-MCP200. Epub 2009 Mar 18.

11.

Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma.

Klimowicz AC, Bose P, Nakoneshny SC, Dean M, Huang L, Chandarana S, Magliocco AM, Wayne Matthews T, Brockton NT, Dort JC.

Eur J Cancer. 2012 Sep;48(14):2166-74. doi: 10.1016/j.ejca.2012.04.010. Epub 2012 Aug 12.

PMID:
22892062
12.

SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma.

Miyawaki A, Ikeda R, Hijioka H, Ishida T, Ushiyama M, Nozoe E, Nakamura N.

Oncol Rep. 2010 May;23(5):1205-12.

PMID:
20372831
13.

Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma.

Negishi A, Masuda M, Ono M, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Nakanishi Y, Kanai Y, Omura K, Hirohashi S, Yamada T.

Cancer Sci. 2009 Sep;100(9):1605-11. doi: 10.1111/j.1349-7006.2009.01227.x. Epub 2009 May 18.

14.

Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach.

Dey KK, Pal I, Bharti R, Dey G, Kumar BN, Rajput S, Parekh A, Parida S, Halder P, Kulavi I, Mandal M.

Tumour Biol. 2015 Dec;36(12):9829-37. doi: 10.1007/s13277-015-3758-7. Epub 2015 Jul 11.

PMID:
26159854
15.

Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.

Bose P, Klimowicz AC, Kornaga E, Petrillo SK, Matthews TW, Chandarana S, Magliocco AM, Brockton NT, Dort JC.

BMC Cancer. 2012 Aug 1;12:332. doi: 10.1186/1471-2407-12-332.

16.

Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Jiang Q, Pan HY, Ye DX, Zhang P, Zhong LP, Zhang ZY.

Tumour Biol. 2010 Oct;31(5):451-9. doi: 10.1007/s13277-010-0054-4. Epub 2010 Jun 8.

PMID:
20532727
17.

High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma.

Moura IM, Delgado ML, Silva PM, Lopes CA, do Amaral JB, Monteiro LS, Bousbaa H.

J Oral Pathol Med. 2014 Mar;43(3):225-31. doi: 10.1111/jop.12115. Epub 2013 Sep 16.

PMID:
24044615
18.

[Expression of galectin-1 in carcinogenesis of oral mucosal epithelium].

Wei KJ, Pan HY, Yang X, Zhong LP, Ye DX, Zhang ZY.

Zhonghua Kou Qiang Yi Xue Za Zhi. 2011 Sep;46(9):524-7. doi: 10.3760/cma.j.issn.1002-0098.2011.09.004. Chinese.

PMID:
22177353
19.

Predictive value of pAKT/PTEN expression in oral squamous cell carcinoma treated with cetuximab-based chemotherapy.

Lyu J, Song H, Tian Z, Miao Y, Ren G, Guo W.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jan;121(1):67-72. doi: 10.1016/j.oooo.2015.09.002. Epub 2015 Sep 7.

PMID:
26577500
20.

Salivary proteomics for oral cancer biomarker discovery.

Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA, Wong DT.

Clin Cancer Res. 2008 Oct 1;14(19):6246-52. doi: 10.1158/1078-0432.CCR-07-5037.

Supplemental Content

Support Center